A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.
Inclusion Criteria:
Exclusion Criteria:
Marietta, Georgia 30060, United States
Kansas City, Missouri 64128, United States
Spartanburg, South Carolina 29303, United States
Fort Sam Houston, Texas 78235-8200, United States
Mezourlo, 41110, Greece
Mezourlo, 41110, Greece
Thessloniki, 57010, Greece
Thessloniki, 57010, Greece
Pescara, 65124, Italy
Hitachi, Ibaraki, 317-0077, Japan
Hitachi, Ibaraki, 317-0077, Japan
Shibuya-ku, 150-8935, Japan
Shibuya-ku, 150-8935, Japan
Saint Petersburg, 191024, Russia
Canterbury Kent, CT1 3NG, United Kingdom
Canterbury Kent, CT1 3NG, United Kingdom
Edinburgh Scotland, EH4 2XU, United Kingdom
Edinburgh Scotland, EH4 2XU, United Kingdom
Sheffield, S10 2JF, United Kingdom
Stoke-on-Trent, ST4 6QG, United Kingdom